1Wild, S, Roglic, G, Green, A, et al. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047–1053.
2Balkau, B (2000) The DECODE study. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Diabetes Metab 26, 282–286.
3Ceriello, A (2005) Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54, 1–7.
4Chia, LR, Schlenk, EA & Dunbar-Jacob, J (2006) Effect of personal and cultural beliefs on medication adherence in the elderly. Drugs Aging 23, 191–202.
5Shane-McWhorter, L & Oderda, LH (2007) Importance of cultural issues in managing a patient with diabetes. Consult Pharm 22, 431–437.
6Ryan, EA, Pick, ME & Marceau, C (2001) Use of alternative medicines in diabetes mellitus. Diabet Med 18, 242–245.
7Grover, JK & Yadav, SP (2004) Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol 93, 123–132.
8Abascal, K & Yarnell, E (2005) Using bitter melon to treat diabetes. J Altern Complement Med 1, 179–184.
9Lans, CA (2006) Ethnomedicines used in Trinidad and Tobago for urinary problems and diabetes mellitus. J Ethnobiol Ethnomed 2, 45.
10Cefalu, WT, Ye, J & Wang, ZQ (2008) Efficacy of dietary supplementation with botanicals on carbohydrate metabolism in humans. Endocr Metab Immune Disord Drug Targets 8, 78–81.
11Yuwai, KE, Rao, KS, Kaluwin, C, et al. (1991) Chemical composition of Momordica charantia L. fruits. J Agric Food Chem 39, 1762–1763.
12Chang, MK, Conkerton, EJ, Chapital, DC, et al. (1996) Chinese melon (Momordica charantia L.) seed: composition and potential use. J Am Oil Chem Soc 73, 263–265.
13Chang, CI, Chen, CR, Liao, YW, et al. (2006) Cucurbitane-type triterpenoids from Momordica charantia. J Nat Prod 71, 1327–1330.
14Harinantenaina, L, Tanaka, M, Takaoka, S, et al. (2006) Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chem Pharm Bull (Tokyo) 54, 1017–1021.
15Li, QY, Chen, HB, Liu, ZM, et al. (2007) Cucurbitane triterpenoids from Momordica charantia. Magn Reson Chem 45, 451–456.
16Tan, MJ, Ye, JM, Turner, N, et al. (2008) Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 15, 263–273.
17Day, C, Cartwright, T, Provost, J, et al. (1990) Hypoglycaemic effect of Momordica charantia extracts. Planta Med 56, 426–429.
18Shibib, BA, Khan, LA & Rahman, R (1993) Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem J 15, 267–270.
19Ali, L, Khan, AK, Mamun, MI, et al. (1993) Studies on hypoglycemic effects of fruit pulp, seed, and whole plant of Momordica charantia on normal and diabetic model rats. Planta Med 59, 408–412.
20Sarkar, S, Pranava, M & Marita, R (1996) Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes. Pharmacol Res 33, 1–4.
21Jayasooriya, AP, Sakono, M, Yukizaki, C, et al. (2000) Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J Ethnopharmacol 72, 331–336.
22Leatherdale, BA, Panesar, RK, Singh, G, et al. (1981) Improvement in glucose tolerance due to Momordica charantia (karela). BMJ 282, 1823–1824.
23Uebanso, T, Arai, H, Taketani, Y, et al. (2007) Extracts of Momordica charantia suppress postprandial hyperglycemia in rats. J Nutr Sci Vitaminol (Tokyo) 53, 482–488.
24Chen, Q, Chan, LL & Li, ET (2003) Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J Nutr 133, 1088–1093.
25Chen, Q & Li, ET (2005) Reduced adiposity in bitter melon (Momordica charanita) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines. Br J Nutr 93, 747–754.
26Ojewole, JA, Adewole, SO & Olayiwola, G (2006) Hypoglycaemic and hypotensive effects of Momordica charantia Linn (Cucurbitaceae) whole-plant aqueous extract in rats. Cardiovasc J S Afr 17, 227–232.
27Virdi, J, Sivakami, S, Shahani, S, et al. (2003) Antihyperglycemic effects of three extracts from Momordica charantia. J Ethnopharmacol 88, 107–111.
28Miura, T, Itoh, C, Iwamoto, N, et al. (2001) Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol (Tokyo) 47, 340.
29Zheng, D, MacLean, PS, Pohnert, SC, et al. (2001) Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J Appl Physiol 91, 1073–1083.
30McCarty, MF (2004) Does bitter melon contain an activator of AMP-activated kinase? Med Hypotheses 63, 340–343.
31Cheng, HL, Huang, HK, Chang, CI, et al. (2008) A cell-based screening identifies compounds from the stem of Momordica charantia that overcome insulin resistance and activate AMP-activated protein kinase. J Agric Food Chem 27, 6835–6843.
32Chuang, CY, Hsu, C, Chao, CY, et al. (2006) Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARα in bitter gourd (Momordica charantia L.). J Biomed Sci 13, 763–772.
33Huang, HL, Hong, YW, Wong, YH, et al. (2008) Bitter melon (Momordica charantia L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats. Br J Nutr 99, 230–239.
34Shih, CC, Lin, CH & Lin, WL (2008) Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res Clin Pract 81, 134–143.
35Yibchok-Anun, S, Adisakwattana, S, Yao, CY, et al. (2006) Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol Pharm Bull 29, 1126–1131.
36Baldwa, VS, Bhandari, CM, Pangaria, A, et al. (1977) Clinical trials in patients with diabetes mellitus of an insulin-like compound obtained from plant source. Ups J Med Sci 82, 39–41.
37Lakholia, AN (1956) The use of bitter gourd in diabetes mellitus. Antiseptic 53, 608–610.
38Srivastava, Y, Venkatakrishna-Bhatt, H & Verma, Y (1993) Antidiabetic and adaptogenic properties of Momordica charantia extract: an experimental and clinical evaluation. Phytother Res 7, 285–289.
39Patel, JC, Dhirawani, MK & Doshi, JC (1968) ‘Karella’ in the treatment of diabetes mellitus. Indian J Med Sci 22, 30–32.
40Khanna, P, Jain, SC, Panagariya, A, et al. (1981) Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 44, 648–655.
41Akhtar, MS (1982) Trial of Momordica charantia Linn (Karela) powder in patients with maturity-onset diabetes. J Pak Med Assoc 32, 106–107.
42Welihinda, J, Karunanayake, EH, Sheriff, MH, et al. (1986) Effect of Momordica charantia on the glucose in maturity onset diabetes. J Ethnopharmacol 17, 277–282.
43Grover, JK & Gupta, SR (1990) Hypoglycemic activity of seeds of Momordica charantia. Eur J Pharmacol 183, 1026–1027.
44Ahmad, N, Hassan, MR, Halder, H, et al. (1999) Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose in NIDDM patients. Bangladesh Med Res Counc Bull 25, 11–13.
45Yeh, GY, Eisenberg, DM, Kaptchuk, TJ, et al. (2003) Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 26, 1277–1294.
46John, AJ, Cherian, R, Subhash, HS, et al. (2003) Evaluation of the efficacy of bitter gourd (Momordica charantia) as an oral hypoglycemic agent – a randomized controlled clinical trial. Indian J Physiol Pharmacol 47, 363–365.
47Tongia, A, Tongia, SK & Dave, M (2004) Phytochemical determination and extraction of Momordica charantia fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). Indian J Physiol Pharmacol 48, 241–244.
48Dans, AM, Villarruz, MV, Jimeno, CA, et al. (2007) The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol 60, 554–559.
49Jadad, AR, Moore, RA, Carroll, D, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17, 1–12.
50Hulin, A (1988) Intoxication aigue par Momordica charantia (sorrossi). A propos de deux cas (Acute intoxication due to Momordica charantia (sorrossi). Study of two cases). Sem Hop 64, 2847–2848.
51Raman, A (1996) Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceace). Phytomedicine 2, 349–362.
52Heiser, CB (1993) The Gourd Book. Norman, OK: University of Oklahoma Press.
53Stepka, W (1974) Antifertility investigations on Momordica. Lloydia 37, 645.
54Saksena, SK (1971) Study of antifertility activity of the leaves of Momordica Linn (Karela). Indian J Physiol Pharmacol 15, 79–80.
55Dixit, VP, Khanna, P & Bhargava, SK (1978) Effects of Momordica charantia L. fruit extract on the testicular function of dog. Planta Med 34, 280–286.
56Chan, WY, Tam, PP & Yeung, HW (1984) The termination of early pregnancy in the mouse by β-momorcharin. Contraception 29, 91–100.
57Leung, SO, Yeung, HW & Leung, KN (1987) The immunosuppressive activities of two abortifacient proteins isolated from the seeds of bitter melon (Momordica charantia). Immunopharmacology 13, 159–171.